SP70 is a novel biomarker of hepatocellular carcinoma.
SP70
diagnostic performance
early recurrence
hepatocellular carcinoma
recurrence-free survival
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
01
2023
accepted:
28
03
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Tumor-specific protein 70 (SP70) was identified as a new biomarker associated with the proliferation and invasion of cancer cells. This study aimed to investigate the expression of SP70 in hepatocellular carcinoma (HCC) and assess its clinical value in the diagnosis and prediction of early HCC recurrence. A total of 1049 subjects from the First Affiliated Hospital of Nanjing Medical University were recruited in this study. Serum SP70, alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence II (PIVKA-II) were measured. The diagnostic performance for HCC was obtained using the receiver operating characteristic (ROC) curve, and recurrence-free survival (RFS) was calculated using the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify predictive factors of RFS. SP70 was highly expressed in HCC cells and HCC tissue. Serum SP70 levels in the HCC group were significantly higher than in the benign liver diseases group and healthy control group ( SP70 is a promising biomarker in diagnosing HCC. High preoperative serum SP70 level is associated with an increased risk of early relapse and could be used as a valuable marker to predict early recurrence of HCC after resection.
Sections du résumé
Background
UNASSIGNED
Tumor-specific protein 70 (SP70) was identified as a new biomarker associated with the proliferation and invasion of cancer cells. This study aimed to investigate the expression of SP70 in hepatocellular carcinoma (HCC) and assess its clinical value in the diagnosis and prediction of early HCC recurrence.
Methods
UNASSIGNED
A total of 1049 subjects from the First Affiliated Hospital of Nanjing Medical University were recruited in this study. Serum SP70, alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence II (PIVKA-II) were measured. The diagnostic performance for HCC was obtained using the receiver operating characteristic (ROC) curve, and recurrence-free survival (RFS) was calculated using the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify predictive factors of RFS.
Results
UNASSIGNED
SP70 was highly expressed in HCC cells and HCC tissue. Serum SP70 levels in the HCC group were significantly higher than in the benign liver diseases group and healthy control group (
Conclusion
UNASSIGNED
SP70 is a promising biomarker in diagnosing HCC. High preoperative serum SP70 level is associated with an increased risk of early relapse and could be used as a valuable marker to predict early recurrence of HCC after resection.
Identifiants
pubmed: 37091138
doi: 10.3389/fonc.2023.1149397
pmc: PMC10117782
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1149397Informations de copyright
Copyright © 2023 Wang, Shi, Wei, Chen, Jin, Gu, Mu, Xu and Pan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Intern Med. 2003 Jul 1;139(1):46-50
pubmed: 12834318
J Clin Oncol. 2011 Dec 20;29(36):4781-8
pubmed: 22105822
Sci Rep. 2020 Feb 13;10(1):2509
pubmed: 32054922
World J Gastroenterol. 2019 Jan 14;25(2):220-232
pubmed: 30670911
Thorac Cancer. 2020 Sep;11(9):2630-2638
pubmed: 32744429
Cancer Med. 2018 Jul;7(7):2925-2933
pubmed: 29767438
Medicine (Baltimore). 2017 Mar;96(11):e5811
pubmed: 28296720
Am J Gastroenterol. 2006 Mar;101(3):524-32
pubmed: 16542289
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Hepatol. 2019 Mar;70(3):440-448
pubmed: 30389551
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer. 2018 Aug 1;124(15):3084-3104
pubmed: 29663340
Gut. 2019 Dec;68(12):2195-2205
pubmed: 31358576
Hepatology. 2012 Oct;56(4):1371-9
pubmed: 22535689
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142893
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
J Hepatol. 2020 Feb;72(2):250-261
pubmed: 31954490
Abdom Imaging. 2014 Aug;39(4):753-60
pubmed: 24699935
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Clin Gastroenterol Hepatol. 2023 Feb;21(2):415-423.e4
pubmed: 35124267
Biomed Pharmacother. 2018 Jul;103:272-283
pubmed: 29656183
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
BMC Cancer. 2018 May 18;18(1):571
pubmed: 29776391
Front Oncol. 2021 Nov 10;11:726213
pubmed: 34900676
Gastroenterology. 2009 Jul;137(1):110-8
pubmed: 19362088
Liver Cancer. 2021 Sep 20;10(6):572-582
pubmed: 34950180
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Hepatol. 2016 Apr;64(1 Suppl):S84-S101
pubmed: 27084040
Front Oncol. 2019 Dec 13;9:1372
pubmed: 31921636
PLoS One. 2012;7(3):e33009
pubmed: 22479355
Gut. 2014 May;63(5):844-55
pubmed: 24531850
Oncol Rep. 2017 Oct;38(4):2251-2258
pubmed: 28765910
J Hepatol. 2019 Jan;70(1):58-65
pubmed: 30213589
Onco Targets Ther. 2015 Dec 31;9:123-9
pubmed: 26770061
World J Surg Oncol. 2022 Apr 25;20(1):132
pubmed: 35468832
Nanoscale. 2017 Sep 21;9(36):13364-13383
pubmed: 28880034
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
Liver Int. 2005 Feb;25(1):16-27
pubmed: 15698394
J Hepatol. 2015 Apr;62(4):848-54
pubmed: 25450201
Oncogene. 2010 Mar 25;29(12):1787-97
pubmed: 20023698
Cancer Manag Res. 2018 Jul 10;10:1947-1958
pubmed: 30022853
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846